A phase 3b, randomized, open-label study of the safety and efficacy of Dolutegravir/Abacavir/Lamivudine once daily compared to Atazanavir and Ritonavir plus Tenofovir/Emtricitabine once daily in HIV-1 infected antiretroviral therapy naïve women

This study is designed to demonstrate the non-inferior antiviral activity of DTG/ABC/3TC fixed dose combination (FDC)…

Treatment outcome of children with HIV infection treated with highly active antiretroviral therapy (HAART)

This is a long-term follow-up study of safety and efficacy of antiretroviral therapy for HIV positive…

A phase 3 multicenter, double-blind, randomized, active comparator-controlled clinical trial to evaluate the safety and efficacy of MK-1439A once-daily versus ATRIPLA once-daily in treatment-naïve HIV-1 infected subjects

This study will compare the antiretroviral activity of MK-1439A, a single-tablet, once-daily (q.d.) fixed-dose combination (FDC)…

Management Using the Latest Technologies In resource-limited settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE)

This is a randomized, open labelled, multicentered international study that will assess the efficacy, safety and…

A pilot study of the pharmacokinetics and safety of Rifabutin 150 mg once daily versus Rifabutin 150 mg thrice weekly with Lopinavir/Ritonavir based HAART in HIV/TB co-infected patients

This is a pilot, randomized, open-label, 2-arm per group, parallel, phase II study that will describe…

A phase 2 intensification study of BIT225, a HIV-1 Vpu inhibitor, in HIV-1 infected individual initiating combination antiretroviral therapy (cART)

This is a phase 2, intensification study of BIT225, a HIV-1 Vpu inhibitor, in HIV-1 Infected…

Collection of key tuberculosis (TB) variables in antiretroviral therapy (ART) programs within the international epidemiologic databases to evaluate AIDS (IeDEA) consortium: Diagnostics, treatment and risk factors for incident TB

The overall goal is to collect, retrospectively and prospectively, key TB variables in ART programs within…

Open label phase 2/3, multicenter, trial to assess the efficacy, safety, tolerance, and pharmacokinetics of sofosbuvir plus ravidasvir in HCV (+/- HIV) chronically infected adults with no or compensated cirrhosis in Thailand and Malaysia

This is an open label phase II/III, multicenter, trial to assess the efficacy, safety, tolerance, and…

Incidence of tuberculosis in difference of CD4 cell count among HIV infected patients receiving antiretroviral treatment and innovative of self assessment tuberculin skin test for latent TB screening in resource limited settings

This study was divided into two parts. The first part will retrospectively assess the incidence of…

A randomised trial of Dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART

This is a randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in…

Investigation of specific immune response pattern in persons with active tuberculosis before and after receiving anti-tuberculous therapy

This study will evaluate the performance of the CD25/CD134 co-expression assay in detecting recall response to…

Disease Progression in HIV-HBV co-infection: Prospective longitudinal cohort

This is a long-term, international multi-site cohort to investigate the relationship between changes on liver biopsy,…

Depression, Vitamin D deficiency and osteoporosis among aging HIV infected and HIV uninfected population in Thailand

This study will assess the depression, vitamin D deficiency and osteoporosis among aging HIV-infected and HIV-uninfected…

An open-label, single arm study to evaluate the week 48 efficacy and safety of a two-drug regimen of Dolutegravir/Lamivudine (DTG/3TC) as a fixed dose combination (FDC), in antiretroviral therapy (ART)-naive HIV-1-infected adolescents, ≥ 12 to < 18 years of age who weigh at least 40 kg

Description: n/a

Prevalence of latent tuberculosis infection and implementation of Isoniazid prophylaxis in Thai prisons (1st year)

This study will assess the prevalence of latent TB infection (LTBI) in prisoners.